A gun salute at the Tower of London has marked the start and end of a national minute's silence in honour of Prince Philip. It was one of many gun salutes fired across the country on the day of the Duke of Edinburgh's funeral.
A gun salute at the Tower of London has marked the start and end of a national minute's silence in honour of Prince Philip. It was one of many gun salutes fired across the country on the day of the Duke of Edinburgh's funeral.
Gautam Gulati plays a henchman to the antagonist Rana.
Edmonton, Alberta--(Newsfile Corp. - May 17, 2021) - Grizzly Discoveries Inc. (TSXV: GZD) (OTCQB: GZDIF) (FSE: G6H) ("Grizzly" or the "Company") is pleased to announce 18 high-priority conductivity anomalies have been identified at its Robocop Property following analysis of the recent 400 line-km Versatile Time Domain Electromagnetic ("VTEM™") and magnetic survey data. Grizzly is planning additional field work over the high-priority anomalies during its 2021 exploration program. The Robocop Property is 100% owned by ...
Levo plans to offer fully financed electric transportation solutions including vehicles, charging infrastructure, and Nuvve’s proprietary vehicle-to-grid (V2G) servicesHOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Evolve Transition Infrastructure LP (“Evolve”) (NYSE American: SNMP) today announced an agreement (the “Agreement”) with Nuvve Holding Corp. (“Nuvve”) (Nasdaq: NVVE), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, and certain investment vehicles managed by Stonepeak Partners LP (“Stonepeak”), a private equity firm specializing in infrastructure investing, to pursue the formation of a new sustainable infrastructure joint venture called Levo Mobility LLC (“Levo”). Upon signing of definitive documents and closing, Levo will utilize Nuvve’s proprietary V2G technology and capital from Stonepeak and Evolve to help accelerate the deployment of electric fleets, including thousands of zero-emission electric school buses for school districts nationwide through “V2G hubs” and Transportation-as-a-Service (“TaaS”). Stonepeak and Evolve plan to deploy up to an aggregate $750 million capital commitment to Levo, with a maximum of 10% of such capital commitment being funded by Evolve. Levo expects to initially focus on electrifying school buses and associated charging infrastructure plus V2G services to provide safer and healthier transportation for children while supporting CO2 emission reduction, renewable energy integration, and improved grid resiliency. Levo also plans to work with commercial fleets such as last-mile delivery, ride hailing and ride sharing, and municipal services. Beyond intelligent charging, Nuvve’s V2G platform allows electric vehicle (“EV”) batteries to store energy, including renewables such as solar and wind, and then safely discharge part of this stored energy back to the grid while parked and plugged in. Additionally, V2G allows EVs to earn revenue by combining energy from multiple batteries to form virtual power plants (“VPPs”) and access energy markets, sell energy back to the grid, and perform services that stabilize the grid. Levo’s initial focus on school buses comes at a time when the Biden-Harris administration has prioritized electrification of the 480,000 school buses in the U.S. through its Infrastructure Plan. Building on this, Lawmakers recently announced a $25 billion bill to electrify school buses and, increasingly, school districts are seeking to convert to zero emission vehicles to provide cleaner rides for students. Today, approximately 95% of school buses are fueled by diesel, but making the switch to electricity is often a challenge due to high upfront capital costs and the complexity of deploying and managing electric charging infrastructure. Levo plans to address these obstacles through flexible options including a fully financed offering that covers the upfront costs of electric buses coupled with a complete charging solution powered by Nuvve’s V2G technology. Levo’s customers would sign contracts for their electric fleets, regardless of size, that would provide for predictable and known budget savings. LEVO JOINT VENTURE DETAILS Pursuant to the Agreement, Nuvve, Stonepeak, and Evolve agree to negotiate in good faith to finalize the definitive agreements for the formation of Levo within 90 days (the “Closing”). Upon Closing, Stonepeak and Evolve will fund Levo’s acquisition and development of agreed assets and infrastructure up to an aggregate capital commitment of $750 million, with such capital commitment expected to be funded 90% by Stonepeak and 10% by Evolve. Stonepeak and Evolve would be granted the ability to upsize their capital commitments upon deployment of the initial $750 million. There can be no assurance that the parties will enter into definitive agreements for the joint venture on the terms described in this press release or at all. In connection with the Agreement, Nuvve, Stonepeak and Evolve also entered into a Securities Purchase Agreement (“SPA”), and a Registration Rights Agreement, each dated as of the date hereof. In addition, Stonepeak received warrants to purchase an aggregate of 5.4 million shares of Nuvve common stock and Evolve received warrants to purchase an aggregate of 600,000 shares of Nuvve common stock (collectively, the “Warrants”). Vesting of certain of the Warrants is conditioned upon Levo deploying varying aggregate amounts of capital over time. In connection with the Agreement, Nuvve also granted Stonepeak and Evolve an option to purchase in aggregate 5 million Nuvve shares of common stock at $50 per share. Nuvve will seek shareholder approval for the issuance of shares of common stock pursuant to the Warrants and SPA to the extent required by Nasdaq rules. Definitive agreements for the joint venture are expected to be signed and the Closing is expected to occur prior to the end of July 2021. Kirkland & Ellis LLP served as legal advisor to Stonepeak, and Coho Strategies and Emergent Strategic Partners provided commercial diligence and strategic planning, DNV served as technical advisor, and KPMG provided financial diligence support to Stonepeak. Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., and Graubard Miller served as legal advisors to Nuvve. Sidley Austin LLP and Hunton Andrews Kurth LLP served as legal advisors to Evolve. FORWARD LOOKING STATEMENTS This press release contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact, included in this press release are forward-looking statements. Any statements that refer to our future financial performance, strategy, expansion plans, future operations, future operating results, estimated revenues, losses, projected costs, prospects, plans and objectives of management, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements in this press release may include, for example, statements about the signing of definitive agreements for, and the anticipated benefits of, the Stonepeak joint venture (the “JV”), and the JV company, Levo, prospects of Nuvve, prospects of Levo, and other statements about the JV and Levo. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “continue,” “goal,” “project” or the negative of such terms or other similar expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us, Stonepeak, Nuvve, Levo, and the JV that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward looking statements. Management cautions all readers that the forward-looking statements contained in this press release are not guarantees of future performance, and we cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in forward-looking statements. Our Annual Report on Form 10-K for the year ended December 31, 2020, our Quarterly Report on Form 10-Q for the three months ended March 31, 2021 and other filings with the SEC discuss some of the important risk factors that may affect our business, results of operations, and financial condition and you are encouraged to read such filings. The forward-looking statements speak only as of the date made, and other than as required by law, we do not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf. ABOUT EVOLVE TRANSITION INFRASTRUCTURE LP Evolve Transition Infrastructure LP is a publicly-traded limited partnership focused on the acquisition, development and ownership of infrastructure critical to the transition of energy supply to lower carbon sources. We own natural gas gathering systems, pipelines and processing facilities in South Texas and continue to pursue energy transition infrastructure opportunities. ADDITIONAL INFORMATION Additional information about Evolve can be found in our documents on file with the SEC which are available on our website at www.evolvetransition.com and on the SEC’s website at www.sec.gov.PARTNERSHIP CONTACTCharles C. WardChief Financial Officerir@evolvetransition.com(713) 800-9477
Faraday Future Enhances FF 91’s Voice Controls and Rear-Seat Video Conferencing Capabilities
monday.com Ltd. ("monday.com"), a work operating system (Work OS) where organizations of any size can create the tools and processes they need to manage every aspect of their work, announced today it has filed a registration statement on Form F-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. monday.com intends to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "MNDY."
Dalton Del Don uses his favorite advanced stat when analyzing pitchers to see what we should expect going forward on the starting front.
Phreesia, the nation’s leader in patient intake, is excited to announce it has been selected by Modern Healthcare as one of the 2021 Best Places to Work in Healthcare. This is the fifth time Phreesia has been named to the magazine’s list.
MADRID (AP) — Luis Suárez had come close to scoring all day long. He had hit the post, missed from close range and been stopped by the goalkeeper a couple of times. As time passed and the misses compounded, Atlético Madrid was seeing its title hopes slip away. It was a few minutes from relinquishing a Spanish league lead it had kept for most of the season. It was a few moments from moving further away from its first league title since 2014. Atlético needed a goal more than ever. It needed its striker like never before. And Suárez came through when it mattered the most. With Atlético being held late and needing the victory to get back in control in the title race, it was Suárez's winner on Sunday that left the team three points away from being able of lifting the trophy in next weekend’s final round. Suárez stood patiently in the middle of the area, waiting for the pass from Yannick Carrasco to come his way. He then calmly drove a low shot into the net, ending a scoring drought of nearly two months and giving Atlético a crucial 2-1 win over Osasuna. The striker took off his jersey and slid by the corner flag to celebrate. A few seconds later he was underneath a pile of his Atlético teammates. The cheers from the fans outside the Wanda Metropolitano Stadium could be heard loudly. “Who better than Suárez to decide a game that seemed to be slipping away from us?” said Atlético coach Diego Simeone, who before the game had predicted this was the striker’s time to shine, saying the team was entering the “Suárez Zone.” Simone was among those celebrating when Atlético signed the Uruguay striker in the beginning of the season after he was surprisingly let go by Barcelona against his wishes. Suárez had a solid season with Atlético despite losing time after being infected with COVID-19. At one stretch, he scored 11 goals in nine matches to help Atlético build its lead. “Luis is an extraordinary player. He arrived with rebellion and a desire to show his worth,” Simeone said. “It's true that he hadn’t been scoring, but he was always there for us.” Suárez’s goal on Sunday was his 20th in the league for Atlético. But he hadn’t scored in five matches, since March 21, coinciding with the team’s slump that had allowed Barcelona and Real Madrid to move closer in the title race. “There are times when it may be easier for a striker to lower his head, to have a letdown,” said the 34-year-old Suárez, who won three league titles with Barcelona. “But I’ve never been like that. I’m proud to always keep fighting.” Atlético's last game will be at relegation-threatened Valladolid on Saturday. Atlético can also clinch the title if defending champion Madrid fails to win its home match against Villarreal. Madrid won 1-0 at Athletic Bilbao on Sunday to stay two points behind. It has the better head-to-head tiebreaker against Atlético. “We depend only on ourselves,” Suárez said. “It will be the most important match of the season.” ___ More AP soccer: https://apnews.com/hub/soccer and https://twitter.com/AP_Sports ___ Tales Azzoni on Twitter: http://twitter.com/tazzoni Tales Azzoni, The Associated Press
The "World - Parquet Panels Of Wood (Excluding Those For Mosaic Floors) - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.
Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Reduced Fat Cereals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Reduced Fat Cereals estimated at US$11.3 Billion in the year 2020, is projected to reach a revised size of US$15.3 Billion by 2027, growing at a CAGR of 4.4% over the period 2020-2027.The U.S. Market is Estimated at $3.1 Billion, While China is Forecast to Grow at 7.1% CAGRThe Reduced Fat Cereals market in the U.S. is estimated at US$3.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2027 trailing a CAGR of 7.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.Select Competitors (Total 55 Featured): Arla Foods Inc.Crowley Food LLCDanone S.A.Dean FoodsGeneral Mills Inc.Kellogg Co.Mondelez Global LLCNestle S.A.PepsiCo, Inc.The Kraft Heinz Company; Key Topics Covered: I. METHODOLOGYII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Influencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Total Companies Profiled: 55 For more information about this report visit https://www.researchandmarkets.com/r/kxmwp9 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
ROME (AP) — Pope Francis on Monday named a new bishop for Hong Kong, tapping the head of his own Jesuit order in the region, the Rev. P. Stephen Chow Sau-Yan, for the politically sensitive position. Chow, a native of Hong Kong, was educated in the U.S. and Ireland before professing his final vows in 2007. He headed two Jesuit-run schools while also teaching at the University of Hong Kong before being made provincial of the Jesuits in the China region in 2018. He replaces the late Bishop Michael Yeong Ming-cheung, who died in 2019. The nomination comes at a sensitive time for Holy See-China relations, following the 2018 landmark agreement over bishop nominations on the Chinese mainland. Critics have said the Vatican sold out the underground Chinese church by signing the agreement, which allows the Chinese government a say in naming bishops. Francis has refrained from commenting on the political tensions in Hong Kong, presumably to avoid riling Beijing. One of Francis’ most vocal critics is the emeritus bishop of Hong Kong, Cardinal Joseph Zen, who retired in 2009. He has bitterly criticized the Vatican’s deal with Beijing. The Associated Press
Should you use oximeters or smartwatches for checking oxygen supply readings?
Futures for Canada's main stock index fell on Monday, tracking weakness in crude prices, while sentiment ...
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours, significantly better than any single drug or combination testedTHCVHS demonstrates superior IOP-lowering and duration relative to glaucoma standard of care, latanoprost San Diego, Calif, May 17, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that in a preclinical study assessing intraocular pressure (IOP)-lowering effects of its novel prodrug, THCVHS combined with netarsudil demonstrated the most significant IOP-lowering effects and duration of activity compared to all other tested single and combined treatments. Data from this study also highlighted THCVHS’ superior IOP-lowering capability and duration of activity as a single agent compared to the current standard of care for the treatment of glaucoma, latanoprost. Elevated IOP is a key risk factor in the progression of glaucoma and the result of fluid build-up in the anterior compartment of the eye. Although current therapies attempt to lower IOP by decreasing fluid production or increasing fluid drainage, many patients respond poorly to specific drugs, build tolerance, or do not experience sufficient lowering of IOP to slow disease progression. More than half of patients eventually require two or more drugs to adequately control their IOP. This leaves a significant need and opportunity for new drugs and classes of therapies, especially ones that increase the magnitude and duration of therapeutic effects. Previous studies conducted with the University of Mississippi (UM) established that THCVHS decreased IOP significantly and over a longer duration than the top two commercially available treatments, latanoprost and timolol. Clinical evidence suggests that combining different classes of IOP-lowering drugs can provide additional benefit for some patients. This new study was designed, in collaboration with UM, to determine the benefit of combining THCVHS with other classes of IOP-lowering drugs, specifically a prostaglandin analogue (latanoprost) and a rho kinase inhibitor (netarsudil). This study demonstrated that THCVHS combined with netarsudil achieved superior IOP-lowering and durability compared to latanoprost. Latanoprost’s average maximum IOP-lowering effect was 21.3% and it returned to baseline after 9 hours; THCVHS combined with netarsudil achieved an average maximum IOP-lowering effect of 32.4% and retained an average reduction in IPO of 26.5% at 9 hours. The data also showed superior IOP-lowering compared to netarsudil combined with latanoprost. This study also reaffirmed THCVHS’ superior ability to significantly lower IOP over a longer duration compared to latanoprost: THCVHS achieved an average maximum reduction in IOP of 27.5% and maintained an average reduction in IOP of 21.1% after 9 hours, at which point latanoprost had returned to baseline. "Our group has had significant experience formulating THCVHS for a variety of therapeutic indications and continues to discover new therapeutic applications for this promising molecule," said Soumyajit Majumdar, PhD, Professor, Department of Pharmaceutics and Drug Delivery at University of Mississippi. “This study again highlights THCVHS’ superiority as a single agent over latanoprost to lower intraocular pressure, including its ability to maintain a significant therapeutic effect beyond nine hours. Importantly, the data also suggests the potential to further enhance the intraocular-pressure-lowering capabilities of THCVHS by combining it with specific alternative classes of IOP-lowering drugs. We anticipate sharing the complete set of data as part of a manuscript to be submitted to a peer-reviewed academic journal." “This new study provides positive new observations regarding THCVHS’ potential to provide advantageous therapeutic benefits for patients, both as a single agent and combined with other drugs, and we plan to fully investigate these possibilities,” said Punit Dhillon, Skye Bioscience, CEO. “These data suggest there is strong potential for THCVHS to be a once-a-day treatment, a desirable outcome for glaucoma treatments. With our recently announced progression on manufacturing and imminent toxicology studies, we continue our progress toward our first-in-human trial for THCVHS that is intended to start later this year.” Study design This study was conducted in collaboration with the University of Mississippi using three in vivo groups. Each group received a single 50 µL dose of THCVHS, latanoprost or netarsudil once daily for the first five days and then a combination of two different drugs once daily for the next five days. In the combined drug study, the second drug was administered 15 minutes after administering the first drug. IOP was measured over the course of 24 hours on days 1, 3 and 5 using single drug treatment and days 6, 8 and 10 using combination drug treatment. The study was performed with the following treatment regimens: Single Drug Regimens Group 1: THCVHS 1.0%Group 2: latanoprost 0.005%Group 3: netarsudil 0.02% Combined Drug Regimens Group 1: THCVHS 1.0% followed by netarsudil 0.02%Group 2: latanoprost 0.005% followed by THCVHS 1.0%Group 3: netarsudil 0.02% followed by latanoprost 0.005% About THCVHSTHCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical ocular formulation under development to treat glaucoma. Developed with rational drug design and biochemical engineering, THCVHS is a proprietary synthetic molecule that enables local delivery of the drug into the eye and reduces the potential for systemic side effects. In preclinical studies, THCVHS demonstrated superior lowering of intraocular pressure, a major risk factor related to irreversible vision loss, compared to the standard-of-care glaucoma treatment. About the University of MississippiThe University of Mississippi, the state's flagship institution, is among the elite group of R-1: Doctoral Universities - Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academics, research, and business. Its 15 academic divisions include a major medical school, nationally recognized schools of accountancy, law and pharmacy, and an Honors College acclaimed for a blend of academic rigor, experiential learning, and opportunities for community action. UM’s research interests include studies of the botanical, pharmacological and chemical properties of the cannabis plant. Since 1968, the marijuana research lab at University of Mississippi’s School of Pharmacy has been the only facility in the United States permitted by the federal government’s National Institute on Drug Abuse to cultivate cannabis for research purposes. About Skye BioscienceSkye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead program, THCVHS, is focused on treating glaucoma, a disease with no cure and the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com. CONTACT Karam Takhar VP, Corporate Development & Investor Relations Email: email@example.com Phone: (858) 410-0266 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Skillz Inc. (“Skillz” or the “Company”) (NYSE: SKLZ). If you are a shareholder of Skillz with more than $200,000 in losses, you should contact the Firm. Skillz operates as a mobile games platform. The Company helps developers build franchises by enabling social competition in their games and other casual e-sport tournaments for players. On March 8, 2021, Wolfpack Research (“Wolfpack”) published a report entitled “Skillz: It Takes Little Skill to See This Spectacular Disaster Coming.” The Wolfpack report described Skillz as “another SPAC preying on retail investors by obtaining a ridiculous valuation for the SPAC merger based on self-serving projections.” Among other issues, the Wolfpack report alleges that Skillz’ top three games, which represent 88% of its revenues, had already plateaued by the third quarter of 2020. The Wolfpack research accuses Skillz of having a history of announcing big deals and partnerships that have “historically amounted to very little, or nothing at all.” As an example, Wolfpack research pointed to the Skillz recent announcement of its partnership with the NFL that pumped Skillz shares to its all-time highs only days before the Company filed an S-1 Form, allowing insiders to sell millions of shares of stock at inflated prices. On this news, Skillz stock price fell sharply from $28.59 per share, or over 14%, to close at $24.45 per share on March 8, 2021. On May 7, 2021, Lowey Dannenberg filed a class action lawsuit against Skillz and several of its officers in the United States District Court for the Northern District of California, on behalf of investors who acquired the Company’s common stock. The Complaint alleges that Defendants, throughout the Class Period, made false and/or misleading statements and/or failed to disclose that: (i) three games responsible for a majority of Skillz’s revenues had declined substantially; (ii) Skillz’s revenue recognition policy misrepresented the financial condition of the company; (iii) unrealistic market growth, specifically in the Android market; and (iv) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. If you are a shareholder of Skillz who purchased Skillz securities between December 16, 2020 and April 19, 2021, inclusive, you have until July 7, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. To participate, learn more, or discuss the issues surrounding the investigation, please contact our attorneys at (914) 733-7256 or via email at firstname.lastname@example.org. Whistleblowers: Persons with non-public information regarding Skillz should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. About Lowey Dannenberg Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors. Contact Lowey Dannenberg P.C.44 South Broadway, Suite 1100 White Plains, NY 10601Tel: (914) 733-7256Email: email@example.com
Siebert Financial Corp. (NASDAQ: SIEB) ("Siebert"), a provider of financial services, today announced great results for the first quarter of 2021, reporting revenue of $18.9 million, an increase of 28% from the first quarter of 2020. In addition, operating income was $3.0 million and basic and diluted earnings per share was $0.07.
"This is one of those unfortunate decisions that had to be made and we move on," Lionel Richie told PEOPLE after Sunday's semi-final episode
The "buy now, pay later" company delivered strong results. But one financial metric, in particular, is the key to its future.
The league had planned access to stadiums limited to 10 percent capacity and exclusively reserved for fans of the home side. All fans were to have shown proof of a negative quick coronavirus test.
A chunk of priceless space rock that fell on the UK will showcase at the Natural History Museum.